Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

AIM The “2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial
Fibrillation” provides recommendations to guide clinicians in the treatment of patients with …

Thyroid hormone (TH) receptors are present in the myocardium and vascular tissue, and
minor alterations in TH concentration can affect cardiovascular (CV) physiology. The …

New biomarkers are being evaluated for their ability to advance the management of patients
with heart failure. Despite a large pool of interesting candidate biomarkers, besides …

Hypothyroidism is a commonly encountered clinical condition with variable prevalence. It
has profound effects on cardiac function that can impact cardiac contractility, vascular …

Iodothyronine deiodinases (DIO) are a family of selenoproteins controlling systemic and
local availability of the major thyroid hormone l-thyroxine (T4), a prohormone secreted by the …

Background: The effects of thyroid dysfunction in patients with preexisting heart failure have
not been adequately studied. We examined the prevalence of thyroid dysfunction and …

Thyroid hormones have long been known to have a range of effects on the cardiovascular
system. However, significant knowledge gaps exist concerning the precise molecular and …

Cardiovascular disease (CVD) remains the leading cause of death worldwide, representing
a major health, social, and economic issue. Thyroid disorders are very common and affect> …

Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signaling
pathway (VSP) have been important additions in the therapy of various cancers, especially …